The deal is expected to close in late Q2 2025, subject to Nevro shareholder and regulatory approval.Globus Medical also reaffirmed its guidance for 2025 net sales of $2.66B to $2.69B and non-GAAP ...

Since November, shares of Globus Medical have displayed continued momentum ... net cash holdings of $270 million, although that Nevro operates with a modest net cash position, but the real ...

Globus Medical closed 2024 on a strong note with record financial performance, driven by sales growth, innovative product launches, and strategic acquisitions. The integration of Nevro Corporation ...

citing the company’s impressive performance and potential synergies from its recent acquisition of Nevro Corp. This acquisition is anticipated to influence Globus Medical’s 2025 financial ...

As previously announced on February 6, given the pending acquisition of Nevro (NVRO) by Globus Medical, Nevro is not issuing FY25 guidance, nor ...

Globus Medical's results underscore a strong quarter ... This outlook could improve further if the pending acquisition of Nevro (purchased for $250 million earlier this month) is finalized ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Globus Medical (GMED – Research Report) and Nevro Corp (NVRO – Research Report). See what stocks are receiving ...

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement ...

BTIG responded by raising its price target for Globus Medical shares to $94, maintaining a Buy rating, citing the company’s impressive performance and potential synergies from its recent acquisition ...